SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in...
from PR Newswire: https://ift.tt/3fttS3u
No comments:
Post a Comment